Summary & Overview
HCPCS Q0174: Thiethylperazine 10 mg Oral Anti-emetic, Chemotherapy Substitute
HCPCS Level II code Q0174 designates thiethylperazine maleate 10 mg oral, an FDA-approved prescription anti-emetic intended as a complete therapeutic substitute for an IV anti-emetic during chemotherapy, with a dosing limit of up to 48 hours. Nationally, this code matters for oncology infusion billing, oral anti-emetic substitution policies, and drug administration practice patterns that affect site-of-service decisions and payer coverage determinations.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical use in chemotherapy settings, typical sites of service (infusion centers and outpatient clinics), and the administrative implications of substituting an oral agent for an IV anti-emetic. The publication outlines benchmarks and coverage considerations relevant to payers and billing teams, describes how the code fits into chemotherapy supportive care workflows, and summarizes what is known about allowable use and dosing constraints tied to the 48-hour regimen.
The report is intended for coding professionals, oncology clinic administrators, and payer policy analysts seeking a concise reference on HCPCS Level II code Q0174, its clinical role, and the operational implications for chemotherapy infusion billing and medication substitution.
Billing Code Overview
HCPCS Level II code Q0174 represents thiethylperazine maleate, 10 mg, oral, FDA-approved prescription anti-emetic, intended for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, with a dosing limit not to exceed a 48-hour regimen. This code identifies a single-dose oral formulation used specifically in the chemotherapy setting to manage nausea and vomiting when an IV anti-emetic would otherwise be administered.
Service Type: Oral prescription anti-emetic used as IV substitute during chemotherapy
Typical Site of Service: Oncology infusion centers, hospital outpatient departments, and clinic settings where chemotherapy is administered
Clinical & Coding Specifications
Clinical Context
A 58-year-old oncology patient receiving outpatient chemotherapy for metastatic colorectal cancer experiences moderate-to-severe nausea and vomiting associated with their infusion. The clinic elects to administer an oral anti-emetic as a complete therapeutic substitute for an intravenous anti-emetic during the chemotherapy encounter due to IV access issues and to avoid additional IV medication administration. The medication administered is Q0174 (thiethylperazine maleate, 10 mg, oral), given as a short-course regimen not to exceed 48 hours. The clinical workflow includes oncologist or oncology nurse assessment of emesis severity, documentation of intent to substitute oral for IV anti-emetic, administration of the first oral dose in the infusion clinic, patient education on dosing and adverse effects, and documentation of the medication, dose, route, indication, and duration in the medical record. Billing is submitted using HCPCS code Q0174 with applicable modifiers to reflect circumstances such as medical necessity, payer requirements, or partial performance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Services | When additional documentation supports substantially greater work, e.g., complex medication counseling or prolonged monitoring related to substituting oral anti-emetic for IV in a complicated patient. |